Showing results (331-340 of 350) with videos related to

Sort By:
Pageof 35
APL Bioengineering|March 13, 2024
Terahertz in vivo imaging of human skin: Toward detection of abnormal skin pathologiesX Qi, K Bertling, J Torniainen, et al.
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|June 2, 2016
A meta-analysis of the efficacy of preoperative surgical safety checklists to improve perioperative outcomesBruce M Biccard, Reitze Rodseth, Larissa Cronje, et al.
Optics Express|September 13, 2019
Increasing the sensitivity of terahertz split ring resonator metamaterials for dielectric sensing by localized substrate etchingK Meng, S J Park, A D Burnett, et al.
Leukemia|October 20, 2019
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 studyJan A Burger, Paul M Barr, Tadeusz Robak, et al.
Hemasphere|June 19, 2026
Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphomaDavid Belada, Faithlore P Gardner, Ana C de Oliveira, et al.
Nature Nanotechnology|December 30, 2022
Highly stable, antiviral, antibacterial cotton textiles via molecular engineeringJi Qian, Qi Dong, Kayla Chun, et al.
Cancers|June 10, 2023
Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial CarcinomaNataliya Mar, Yousef Zakharia, Alejandro Falcon, et al.
The Lancet. Oncology|February 6, 2025
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 studyMichael Wang, Wojciech Jurczak, Marek Trneny, et al.
The Lancet. Haematology|March 25, 2017
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trialRuben A Mesa, Alessandro M Vannucchi, Adam Mead, et al.
Blood Advances|June 15, 2019
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studiesSteven E Coutre, John C Byrd, Peter Hillmen, et al.
Pageof 35